HOPE evaluates a novel disease-modifying therapy that elicits gamma-frequency brain activity through non-invasive sensory stimulation. Cambridge, Massachusetts-based Cognito aims to slow the progression of Alzheimer’s disease from the comfort of a patient’s home.
This evaluation looks at MRI, cerebrospinal fluid and plasma biomarkers. Cognito believes it could offer key insights into Alzheimer’s progression and may help see earlier predictive responses to Cognito therapy. The company believes it may help to better identify patients and new disease areas that respond best to treatment.
Cognito remains on track to complete the study within projected timelines, with more than 240 patients currently enrolled across 60 U.S. sites. This data could add to recently published positive results from the Phase 2 OVERTURE study.
“While several experimental drugs focus on addressing well-known amyloid plaques and tau tangles in the brain, Cognito is exploring an innovative, non-invasive medical device designed to target additional factors contributing to Alzheimer’s disease, by targeting abnormal electrical activities in the brain,” said Brent Vaughan, CEO. “This novel approach presents an opportunity to address Alzheimer’s disease using a different modality, offering a potential new treatment option for those affected by this devastating condition.”
